SNRPA and Cisplatin Resistance in Lung Cancer
Author Information
Author(s): Fan Weina, Huang Jian, Tian Fanglin, Hong Xin, Zhu Kexin, Zhan Yuning, Li Xin, Wang Xiangyu, Wang Xin, Cai Li, Xing Ying
Primary Institution: Harbin Medical University Cancer Hospital
Hypothesis
SNRPA modulates cisplatin resistance in lung adenocarcinoma through alternative splicing of ERCC1 exon 8.
Conclusion
SNRPA enhances cisplatin resistance in lung adenocarcinoma by promoting the expression of ERCC1 exon 8, which is crucial for DNA repair.
Supporting Evidence
- SNRPA knockout reversed cisplatin resistance in lung adenocarcinoma cells.
- SNRPA overexpression enhanced cisplatin resistance.
- High SNRPA expression predicted poor overall survival in patients treated with cisplatin.
- ELAVL1 was found to stabilize SNRPA mRNA, enhancing its expression.
- ERCC1 exon 8 skipping was regulated by SNRPA, affecting DNA repair capacity.
- Mouse models showed that SNRPA knockout increased sensitivity to cisplatin.
- Bioinformatics analysis identified SNRPA as a prognostic indicator in lung adenocarcinoma.
Takeaway
SNRPA helps cancer cells resist a common chemotherapy drug by changing how a gene is spliced, which helps repair DNA damage.
Methodology
The study used CRISPR/Cas9 and shRNA techniques to manipulate SNRPA expression in lung adenocarcinoma cell lines and analyzed the effects on cisplatin resistance and DNA repair.
Potential Biases
Potential biases may arise from the selection of cell lines and the experimental conditions used.
Limitations
The study primarily focuses on in vitro and in vivo models, which may not fully replicate human responses.
Participant Demographics
The study analyzed data from 1205 patients with lung adenocarcinoma, including those treated with platinum-based chemotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website